CanSino Biologics Inc. has released the latest Terms of Reference for its Remuneration and Assessment Committee. According to the announcement, the Board established this committee to refine the governance structure and oversee both remuneration and performance evaluations for directors and senior management.

The guidelines outline the composition of the committee, which must comprise at least three directors with a majority being independent non-executive directors. The committee is led by a chair who is also an independent non-executive director. Its duties include reviewing and proposing remuneration packages, performance appraisal standards, and compensation arrangements related to any termination or dismissal of executives.

The committee is further responsible for reviewing and supervising the company’s overall remuneration system, ensuring fairness and alignment with contractual terms. The announcement also specifies procedural details on how meetings are called, voting rules, and requirements for documentation and confidentiality. All resolutions passed by the committee must be reported to the Board for consideration and, where necessary, further approval by shareholders.

The updated terms underscore the commitment to transparent and standardized practices, reflecting statutory and regulatory requirements. The newly published provisions take effect upon Board approval and are intended to maintain compliance with all relevant listing and governance regulations.